Antigenics Inc. - Sales Analysis Snapshot

Business Description
This Report provides a comprehensive Sales & Margin summary analysis for Antigenics Inc. Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.

Antigenics Inc.. The Group's principal activity is to develop technologies and products to treat cancers and infectious diseases. It primarily develops Oncophage (R). Lead development programs include immunotherapeutics that are based on a specific class of proteins known as heat shock proteins (HSPs) and an immune system adjuvant called QS-21. The products under development include Oncophage (R), Aroplatin, ATRA-IV, AG-702, QS-21 Adjuvant, CD91 and CD1. The related business activities include product research and development activities, regulatory and clinical affairs, establishing manufacturing capabilities, production for clinical trials and administrative and corporate development activities.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report